Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis by Elena Iemma | May 16, 2024
Immunogenicity risk assessment of synthetic peptide drugs and their impurities by Elena Iemma | Jul 27, 2023Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020 by Annie De Groot | Jun 30, 20202020 TCWP